This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Novartis acquires GSK’s cancer drug assets for $14.5bn up front
21 Aug 2015
Essentially ending its quest to be a leading oncology company, GlaxoSmithKline PLC divested to Novartis AG several cancer assets for $14.5bn up front, plus a $1.5bn development milestone dependent upon the results (specifically the achievement of a survival endpoint) in COMBI-d, a Phase III trial comparing the combination of dabrafenib (the BRAF inhibitor Tafinlar) and trametinib (the MEK inhibitor Mekinist) with dabrafenib alone in patients with stage IIIC or metastatic (stage IV) BRAF V600E/K mutation-positive cutaneous melanoma.
Payment Includes Cash
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?